Life Sciences Market Research Report
Report Filter Reset All
Sort By Price
Published Date
Category
Publishers
Report Type
Continents
Regions
Global Hemin Drugs Market Insights, Forecast to 2025
Hemin is an iron-containing porphyrin with chlorine that can be formed from a haem group, such as haem b found in the haemoglobin of human blood. The global ...
$3,900.00 22 May, 2019 | QYResearch
Global Hemin Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Hemin is an iron-containing porphyrin with chlorine that can be formed from a haem group, such as haem b found in the haemoglobin of human blood. T...
Global Panhematin Drugs Market Insights, Forecast to 2025
Panhematin is an iron-containing porphyrin with chlorine that can be formed from a haem group, such as haem b found in the haemoglobin of human blood. The gl...
$3,900.00 22 May, 2019 | QYResearch
Global Panhematin Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Panhematin is an iron-containing porphyrin with chlorine that can be formed from a haem group, such as haem b found in the haemoglobin of human blo...
Global Swedish Porphyria Market Insights, Forecast to 2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deamina...
$3,900.00 22 May, 2019 | QYResearch
Global Swedish Porphyria Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinog...
Global Acute Intermittent Porphyria Drugs Market Insights, Forecast to 2025
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic dis...
$3,900.00 22 May, 2019 | QYResearch
Global Acute Intermittent Porphyria Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant met...
Global Acute Intermittent Porphyria Treatment Market Insights, Forecast to 2025
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic dis...
$3,900.00 22 May, 2019 | QYResearch
Global Acute Intermittent Porphyria Treatment Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant met...
Global Acute Intermittent Porphyria Therapeutics Market Insights, Forecast to 2025
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic dis...
$3,900.00 22 May, 2019 | QYResearch
Global Acute Intermittent Porphyria Therapeutics Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant met...
Global Swedish Porphyria Drugs Market Insights, Forecast to 2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deamina...
$3,900.00 22 May, 2019 | QYResearch
Global Swedish Porphyria Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinog...
Global Swedish Porphyria Treatment Market Insights, Forecast to 2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deamina...
$3,900.00 22 May, 2019 | QYResearch
Global Swedish Porphyria Treatment Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinog...
Global Swedish Porphyria Therapeutics Market Insights, Forecast to 2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deamina...
$3,900.00 22 May, 2019 | QYResearch
Global Swedish Porphyria Therapeutics Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinog...
Global Nelarabine Market Insights, Forecast to 2025
Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Nelarabine market is valued at xx million US$ in 2018 and will reac...
$3,900.00 22 May, 2019 | QYResearch
Global Nelarabine Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Nelarabine market is valued at xx million US$ in 2018 and...
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
